<DOC>
	<DOCNO>NCT02232620</DOCNO>
	<brief_summary>This open label , multi-center , phase II study BBI503 administer adult patient advance gastrointestinal stromal tumor exhaust currently approve standard anti-cancer treatment option . BBI503 administer orally , daily , continuous 28-day cycle dose 300 mg daily . Cycles repeat patient longer clinically benefit therapy due disease progression , adverse event , another discontinuation criterion . Safety , tolerability efficacy BBI503 assess duration study treatment .</brief_summary>
	<brief_title>A Study BBI503 Adult Patients With Advanced Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) , local regulatory requirement , permission use private health information accordance Health Insurance Portability Accountability Act ( HIPPA ) prior studyspecific screening procedure Histologically cytologically confirm gastrointestinal stromal tumor metastatic , unresectable , recurrent ; currently approve , standard anticancer treatment option available . ≥ 18 year age Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last BBI503 dose Females childbearing potential must negative serum pregnancy test Alanine transaminase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) , ≤ 3.5 x ULN presence primary metastatic hepatic lesion Hemoglobin ( Hgb ) ≥ 10 g/dl Total bilirubin ≤ 1.5 x ULN Creatinine ≤ 1.5 x ULN creatinine clearance &gt; 50 mL/min/1.73 m^2 patient creatinine level institutional normal . Absolute neutrophil count ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L PT ≤ 16 second PTT ≤ 1.5 x ULN Life expectancy ≥ 3 month A patient gastrointestinal stromal tumor ( GIST ) must also meet follow criterion : Must either positive immunostaining CD117antigen , contain GIST associate KIT PDGFRα mutation . Must disease metastatic locally advanced unresectable Must receive prior treatment imatinib sunitinib , must disease progression treatment agent , document intolerance agent , candidate treatment agent . Must also fail eligible treatment regorafenib . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within 7 day first dose BBI503 . Patients may begin BBI503 date determine investigator medical monitor sponsor provide minimum 7 day since last receiving anticancer treatment , prior treatmentrelated AEs resolve deem irreversible . Major surgery within 4 week prior first dose ( require general anesthesia and/or inpatient hospitalization recovery ) . Any known symptomatic untreated brain metastasis require increase steroid dose within 2 week prior start study . Patients treat brain metastasis must stable 4 week completion treatment . Posttreatment image documentation stability require within 4 month start study . Patients must clinical symptom brain metastasis must either steroids stable dose steroid least 2 week prior protocol enrollment . Patients know leptomeningeal metastasis exclude , even treat . Pregnant breastfeeding Significant gastrointestinal disorder ( ) , opinion Principal Investigator , ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric small intestine resection ) Unable unwilling swallow BBI503 capsule daily Uncontrolled intercurrent illness include , limited ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement ( e.g . reliable transportation ) . Patients history malignancy tumor interest except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease &gt; 3 year . Abnormal ECGs clinically significant QT prolongation QTc &gt; 480 msec , clinically significant cardiac enlargement hypertrophy , new bundle branch block , sign active ischemia . Patients evidence prior infarction New York Heart Association ( NYHA ) functional class II , III , IV exclude , patient mark arrhythmia Wolff Parkinson White pattern complete atrioventricular ( AV ) dissociation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>